Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Avatrombopag, rilzabrutinib and COVID-19 updates in ITP

Barbara Skopec • 28 May 2021
EHA 2021
Immune Thrombocytopenia Non-Malignant Avatrombopag Rilzabrutinib

Barbara Skopec, MD, PhD, University Medical Centre Ljubljana, Ljublyjana, Slovenia, shares which abstracts she is most looking forward to at the virtual European Hematology Association (EHA) Congress 2021, in particular highlighting novel data on avatrombopag and rilzabrutinib for patients with immune thrombocytopenia (ITP) and the management of COVID-19 in patients with ITP.

Disclosures

Barbara Skopec, MD, PhD, has received consultancy fees from Amgen and Novartis.

More from Barbara Skopec

3:02
Real-world analysis of safety and efficacy of romiplostim for ITP
Barbara Skopec • 28 May 2021

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals